Precigen Chief Financial Officer Harry Thomasian Jr. sold 200,000 shares of common stock for approximately $1.11 million under a pre-arranged Rule 10b5-1 trading plan. The transactions occurred between June 29 and July 1, 2026, at a weighted average price of $5.57 per share, reducing his direct holdings by 36% to 354,535 shares. The sales were executed as Precigen shares neared a multi-year high of $6.04, with the company reporting first-quarter revenue of $23.3 million and receiving FDA orphan drug designation for its Papzimeos treatment. Because the trades were part of a non-discretionary plan, they are not necessarily a red flag for investors.
Precigen IncCFO sold $1.1M shares under pre-arranged plan, reducing holdings by 36%, but plan is non-discretionary and not necessarily a red flag.